Abstract
Diabetes is associated with an increased risk of Coronavirus disease 2019 (COVID-19) vulnerability and mortality. COVID-19 vaccines significantly reduce the risks of serious COVID-19 outcomes, but the impact of COVID-19 vaccines including their effectiveness and adverse effects in patients with diabetes are not well known yet. Here, we showed that 61.1% patients with type 2 diabetes, but not healthy controls, exhibited aggravated insulin resistance towards the booster shots of the COVID-19 vaccine. Furthermore, we showed that COVID-19 vaccination once a week also impaired insulin sensitivity in healthy mice after four weeks. We further showed that metformin, a common anti-diabetic medication, improved the impaired insulin signaling induced by COVID-19 vaccination in mice. This study suggests clinical implications for the close monitoring of glycemic control in diabetic patients after receiving COVID-19 vaccines and indicates the beneficial action of metformin in counteracting insulin signaling variations induced by COVID-19 vaccination in diabetic patients.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2300069830
Funding Statement
This study was kindly supported by Health@InnoHK Initiative Fund from the Hong Kong SAR Government (ITC RC/IHK/4/7 to ZX.B.), Key-Area Research and Development Program of Guangdong Province (2020B1111110003 to ZX.B.), NSFC Excellent Young Scientist Scheme (32322091 to HLX.W.), Innovation and Technology Support Programme from the Hong Kong SAR Government (ITS/058/22MS, to HLX.W.) and General Research Grants from the Hong Kong SAR Government (22104123, to HLX.W.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The human study was approved by the Research Committee on the Use of Human and Animal Subjects in Teaching and Research at Hong Kong Baptist University (REC/22-23/0277) and registered on Chinese Clinical Trial Registry (ChiCTR2300069830).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
